What test is included in risk stratification for asymptomatic cardiovascular disease?

What test is included in risk stratification for asymptomatic cardiovascular disease?

• A. Lipid panel
• B. Echocardiography
• C. Baseline ECG
• D. Chest X-ray

Answer: (A)

Assessing risk in people without symptoms focuses on modifiable factors, especially lipid levels. A fasting lipid panel provides LDL cholesterol, HDL cholesterol, and triglycerides, which are essential inputs for ASCVD risk calculators. These calculators estimate a person’s 10-year (and lifetime) risk and help determine whether preventive therapies, such as statins, are appropriate. Imaging or noninvasive tests like echocardiography, baseline ECG, and chest X-ray aren’t used routinely to stratify risk in asymptomatic individuals because they don’t reliably predict future ASCVD events and aren’t cost-effective screening tools. Echocardiography looks for structural heart disease and is reserved for people with symptoms or abnormal findings; baseline ECG can yield false positives and has limited predictive value in screening asymptomatic populations; chest X-ray does not contribute meaningful risk stratification for ASCVD. So, the lipid panel best fits risk stratification for someone without symptoms because it directly informs the estimation of future risk and guides preventive decisions.

Assessing risk in people without symptoms focuses on modifiable factors, especially lipid levels. A fasting lipid panel provides LDL cholesterol, HDL cholesterol, and triglycerides, which are essential inputs for ASCVD risk calculators. These calculators estimate a person’s 10-year (and lifetime) risk and help determine whether preventive therapies, such as statins, are appropriate.

Imaging or noninvasive tests like echocardiography, baseline ECG, and chest X-ray aren’t used routinely to stratify risk in asymptomatic individuals because they don’t reliably predict future ASCVD events and aren’t cost-effective screening tools. Echocardiography looks for structural heart disease and is reserved for people with symptoms or abnormal findings; baseline ECG can yield false positives and has limited predictive value in screening asymptomatic populations; chest X-ray does not contribute meaningful risk stratification for ASCVD.

So, the lipid panel best fits risk stratification for someone without symptoms because it directly informs the estimation of future risk and guides preventive decisions.